Management of Prameha (Type 2 Diabetes Mellitus) with Ayurveda Formulations as Adjuvant Therapy: A Case Report
DOI:
https://doi.org/10.63247/3048-7390.vol.2.issue2.4Keywords:
Prameha, Ayurveda, Type 2 Diabetes Mellitus, Madhumeharī cūrṇa, Triphalā guggulu, Paṭolakaturohiṇyādi kaṣāyaAbstract
Introduction: Prameha, described in Āyurveda as a tridoṣaja and medo-pradoṣaja disorder, shares close clinical correlation with Type 2 Diabetes Mellitus (T2DM). It is characterized by polyuria or turbid urine (prabhūta/avila mūtra) and is associated with unhealthy dietary habits (apathya-sevana), sedentary lifestyle, and hereditary predisposition (sahaja hetu).
Case Information: A 37-year-old woman with a 10-year history of T2DM was receiving conventional therapy comprising high-dose insulin (54 units/day) and oral hypoglycemic agents. Despite ongoing treatment, she had persistent polyuria (bahu-mūtratā), weakness (daurbalya), and burning sensation in the feet (pāda-dāha).
Intervention: An integrative regimen comprising Paṭolakaturohiṇyādi kaṣāya tablets, Triphala guggulu, and Madhumeharī cūrṇa was prescribed alongside dietary and lifestyle modifications, while conventional therapy was continued initially and tapered gradually.
Results: Over five months, HbA1c reduced from 8.5% to 6.1%, fasting blood glucose normalized, symptoms resolved, and insulin was discontinued. Oral hypoglycemic doses were also reduced.
Conclusion: This case demonstrates the potential of Āyurvedic formulations as adjuvant therapy in the integrative management of T2DM, enabling reduction of pharmacological dependence and improvement in quality of life.
Keywords: Prameha, Āyurveda, Type 2 Diabetes Mellitus, Madhumeharī cūrṇa, Triphalā guggulu, Paṭolakaturohiṇyādi kaṣāya
References
1) Sushruta Samhita, Nidana Sthana, Prameha Nidanam Adhyaya, 6/6. Available from https://niimh.nic.in/ebooks/esushruta (Accessed on 18 July 2025)
2) Caraka Samhita, Nidana sthana, Prameha Nidanam Adhyaya, 4/7. Available from: http://niimh.nic.in/ebooks/ecaraka (Accessed on 18 July 2025).
3) Sushruta Samhita, Sutra Sthana, Doshadhatumalakshayavruddhivigyaneeya Adhyaya, 15/32. Available from https://niimh.nic.in/ebooks/esushruta (Accessed on 19 July 2025)
4) Dalhana on Sushruta Samhita, Nidana Sthana, Prameha Nidanam, 6/4. Available from https://niimh.nic.in/ebooks/esushruta (Accessed on 18 July 2025)
5) Caraka Samhita, Chikitsa sthana, Pramehachikitsitam Adhyaya, 6/4. Available from: http://niimh.nic.in/ebooks/ecaraka (Accessed on 19 July 2025).
6) Sharma H, Chandola HM. Prameha in Ayurveda: correlation with obesity, metabolic syndrome, and diabetes mellitus. Part 1-etiology, classification, and pathogenesis. J Altern Complement Med. 2011 Jun;17(6):491-6. doi: 10.1089/acm.2010.0396. Erratum in: J Altern Complement Med. 2011 Jul;17(7):661. PMID: 21649515.
7) Solis-Herrera C, Triplitt C, Reasner C, et al. Classification of Diabetes Mellitus. [Updated 2018 Feb 24]. In: Feingold KR, Ahmed SF, Anawalt B, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK279119/
8) Tsalamandris S, Antonopoulos AS, Oikonomou E, Papamikroulis GA, Vogiatzi G, Papaioannou S, Deftereos S, Tousoulis D. The Role of Inflammation in Diabetes: Current Concepts and Future Perspectives. Eur Cardiol. 2019 Apr;14(1):50-59. doi: 10.15420/ecr.2018.33.1. PMID: 31131037; PMCID: PMC6523054.
9) Ashtangahridaya, Sutrasthana, Shodanadigansangraha Adhyaya, 15/15. Available from https://vedotpatti.in/samhita/Vag/ehrudayam/?mod=read (Accessed on 21 July 2025)
10) Kumar N, Singh S, Manvi, Gupta R. Trichosanthes dioica Roxb.: An overview. Pharmacogn Rev. 2012 Jan;6(11):61-7. doi: 10.4103/0973-7847.95886. PMID: 22654406; PMCID: PMC3358970.
11) Almeleebia TM, Alsayari A, Wahab S. Pharmacological and Clinical Efficacy of Picrorhiza kurroa and Its Secondary Metabolites: A Comprehensive Review. Molecules. 2022 Nov 29;27(23):8316. doi: 10.3390/molecules27238316. PMID: 36500409; PMCID: PMC9738980.
12) Bulle S, Reddyvari H, Nallanchakravarthula V, Vaddi DR. Therapeutic Potential of Pterocarpus santalinus L.: An Update. Pharmacogn Rev. 2016 Jan-Jun;10(19):43-9. doi: 10.4103/0973-7847.176575. PMID: 27041873; PMCID: PMC4791987.
13) Nayak A. Evaluation of Antidiabetic and Lipid-Lowering Effect of Marsdenia tenacissima and Sphaeranthus indicus. Journal of Pharmacology and Toxicology, 2023:18: 10-16.DOI: 10.3923/jpt.2023.10.16 URL: https://scialert.net/abstract/?doi=jpt.2023.10.16
14) Sharma R, Amin H, Ruknuddin G and Prajapati P. Antidiabetic claims of Tinospora cordifolia (Willd.) Miers: Critical appraisal and role in therapy. Asian Pacific Journal of Tropical Biomedicine. 2015. 5. 68-78. 10.1016/S2221-1691(15)30173-8. Available from: https://www.researchgate.net/publication/274713079_Antidiabetic_claims_of_Tinospora_cordifolia_Willd_Miers_Critical_appraisal_and_role_in_therapy
15) Kumari S, Anmol, Bhatt V, Patil S S, Sharma U. Cissampelos pareira L.: A review of its traditional uses, phytochemistry, and pharmacology, Journal of Ethnopharmacology, Volume 274, 2021, 113850, ISSN 0378-8741
16) Yadav Y. ANTI-INFLAMMATORY AND ANTI-MICROBIAL ACTION OF TRIPHALA GUGGULU: A REVIEW. 13. 2022. Available from: https://www.researchgate.net/publication/362153302_ANTI-INFLAMMATORY_AND_ANTI-MICROBIAL_ACTION_OF_TRIPHALA_GUGGULU_A_REVIEW/citation/download
17) Murthy K, Jagadale S, Solunke R.S. et al. Antidiabetic potential of Triphala Guggul - an ayurvedic formulation in alloxan-induced diabetes animal model. International Journal of Research in Pharmaceutical Sciences. 11. 315-322. 10.26452/ijrps. v11i1.1823. Available from:https://www.researchgate.net/publication/338475839_Antidiabetic_potential_of_Triphala_Guggul_-_an_ayurvedic_formulation_in_alloxan-induced_diabetes_animal_model
18) Bairwa VK, Kashyap AK, Meena P, Jain BP. Triphala's characteristics and potential therapeutic uses in modern health. Int J Physiol Pathophysiol Pharmacol. 2025 Apr 25;17(2):19-36. doi: 10.62347/OBSS5026. PMID: 40401115; PMCID: PMC12089839.
19) Tsalamandris S, Antonopoulos AS, Oikonomou E, Papamikroulis GA, Vogiatzi G, Papaioannou S, Deftereos S, Tousoulis D. The Role of Inflammation in Diabetes: Current Concepts and Future Perspectives. Eur Cardiol. 2019 Apr;14(1):50-59. doi: 10.15420/ecr.2018.33.1. PMID: 31131037; PMCID: PMC6523054.
20) Antonio C. New Insights on Oxidative Stress and Diabetic Complications May Lead to a “Causal” Antioxidant Therapy. Diabetes Care 1 May 2003; 26 (5): 1589–1596. https://doi.org/10.2337/diacare.26.5.1589
21) Yadav Y. ANTI-INFLAMMATORY AND ANTI-MICROBIAL ACTION OF TRIPHALA GUGGULU: A REVIEW. 13. 2022. Available from: https://www.researchgate.net/publication/362153302_ANTIINFLAMMATORY_AND_ANTI-MICROBIAL_ACTION_OF_TRIPHALA_GUGGULU_A_REVIEW/citation/download
22) Eingold KR. Dyslipidemia in Patients with Diabetes. [Updated 2023 Dec 4]. In: Feingold KR, Ahmed SF, Anawalt B, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK305900/
23) The Ayurvedic Formulary of India, Department of Ayurveda, Yoga & Naturopathy, Unani, Siddha, and Homeopathy (AYUSH), Ministry of Health and Family Welfare, Government of India, New Delhi, First ed., vol. part III. 2011, p. 141
24) Bhatnagar, S., Yadav, K., & Bhardwaj, S. (2025, March 6). Effect of Madhumehari Churna as an Adjuvant to Insulin Therapy in the management of Type 1 and Type 2 Diabetes Mellitus: Two Case Reports. International Journal of AYUSH Case Reports, 9(1), 20-29. https://doi.org/https://doi.org/10.70805/ija-care.v9i1.686
25)Bhatnagar S, Yadav K, Bhardwaj S, Sharma K, Raghuvanshi M & Veena. Review of Madhumehari Churna: An ayurvedic polyherbal formulation used in management of Diabetes mellitus. Vol.38. 2024.15-23
Downloads
Additional Files
Published
Issue
Section
License
Copyright (c) 2025 Dr. Ambika Hegde, Prof. (Dr.) Shailza Bhatnagar, Dr. Kalpana Yadav, Dr. Deepak Jangid (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
\
